MTOR and neoplasm: RNA transcriptome sequencing of the subject’s tumor showed overexpression of SLC29A11 (Z-score = 3.3) indicating sensitivity to gemcitabine as well as activation of the biological pathways mTOR, CSF1R, EPHA2, SLC29A1, suggesting possible beneficial treatment with a combination of everolimus, gemcitabine, doxycycline and dasatinib.